|
시장보고서
상품코드
1789418
벤라팍신(Venlafaxine) 시장 : 적응증별, 유형별, 제형 및 용량별, 연령층별, 유통채널별, 최종사용자별, 지역별Venlafaxine Market, By Indication, By Type, By Dosage Form and Strength, By Age Group, By Distribution Channel, By End User, By Geography |
||||||
벤라팍신 시장은 2025년에는 35억 4,000만 달러, 2032년에는 52억 6,000만 달러에 이를 것으로 예측되고, 2025-2032년까지의 연평균 성장률(CAGR)은 5.82%를 보일 것으로 예측됩니다.
| 보고 범위 | 보고서 세부정보 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 35억 4,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 2025-2032년 CAGR : | 5.82% | 2032년 금액 예측 | 52억 6,000만 달러 |
벤라팍신 세계 시장은 세계 정신 질환의 유병률이 증가함에 따라 보다 광범위한 항우울 의약품 시장에서 중요한 부분이 되었습니다. 세로토닌 노르에피네프린 재흡수 억제제(SNRI)인 벤라팍신은 우울증, 전반적인 불안 장애, 사교 불안 장애, 공황 장애 치료에 중요한 치료 옵션으로 자리를 잡고 있습니다.
세로토닌과 노르에피네프린 모두 신경전달물질의 재흡수를 억제하는 이중 작용기전은 특정 환자 집단에서 기존의 선택적 세로토닌 재흡수 억제제(SSRI)에 비해 더 높은 효과를 제공합니다. 시장에는 즉시 방출형 제형과 서방형 제형이 모두 있으며, 환자의 컴플라이언스 향상과 부작용 완화를 위해 서방형 제형이 선호되고 있습니다. 정신건강에 대한 의식 증가, 정신과 치료의 비종교화, 신흥국에서의 헬스케어 인프라의 확대 등이 시장의 꾸준한 성장에 기여하고 있습니다. 게다가, 특허 만료에 따른 제네릭 의약품의 출현으로, 벤라팍신은 더 많은 환자들에게 이용하기 쉬운 약이 되어, 세계의 다양한 지역 및 헬스케어 시스템에서 시장 침투를 더욱 뒷받침하고 있습니다.
시장 역학
벤라팍신 세계 시장은 몇 가지 중요한 촉진요인에 의해 지원됩니다. 가장 중요한 촉진요인은 세계 우울증과 불안 장애의 유병률이 상승하고 있다는 것이며, WHO의 추계에 의하면, 세계에서 3억명 이상이 영향을 받고 있습니다. 정신 건강이 전신 건강의 중요한 요소라는 인식이 높아지고 정신과 치료를 둘러싼 편견의 감소도 함께 진단률과 치료를 요구하는 행동이 증가하고 있습니다. 우울증과 불안증을 동시에 치료하는 뛰어난 효능으로 인해 건강 관리 제공업체가 기존의 항우울제보다 SNRI를 선호하는 것도 큰 촉진요인이 되었습니다. 우울증이나 불안장애에 걸리기 쉬운 노년 인구가 확대되고 있는 것도, 시장 수요를 한층 더 높이고 있습니다.
그러나 시장은 다수의 제네릭 의약품의 가용성으로 인해 제조업체의 이익률이 현저하게 저하되고, 보다 뛰어난 안전성 프로파일을 가질 수 있는 신규 항우울제 클래스의 상승 등 현저한 억제요인에 직면하고 있습니다. 특허 클리프(특허 절벽)의 영향으로 가격 경쟁이 격화되고 있으며, 새로운 제제와 적응증에 대한 엄격한 규제 요건이 추가 과제가 되고 있습니다. 이탈 증상, 성기능 장애, 심혈관계에 대한 우려 등 벤라팍신과 관련된 부작용은 특정 환자 집단에서 처방을 제한할 수 있습니다. 그러나 정신건강의 인프라가 급속히 발전하고 있는 신흥국 시장이나 환자의 컴플라이언스를 높여 부작용을 경감할 수 있는 신규 약물전달 시스템의 개발에는 큰 비즈니스 기회가 존재합니다. 개인화된 의료 및 약리 유전체학의 추세가 증가하면 개별 환자의 유전자 프로파일을 기반으로 하는 표적화된 벤라팍신 치료의 기회가 생겨 치료 성과 및 시장 성장 전망을 개선할 수 있습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 벤라팍신 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모와 복합 연간 성장률(CAGR%)을 제공합니다.
- 또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 행렬에 대해 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 엔터프라이즈 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 매개변수를 기반으로 세계 벤라팍신 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 타이핑, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 이 조사 보고서는 투자자, 공급업체, 제품 제조업체, 판매자, 신규 참여자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자는 세계의 벤라팍신 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제 요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- PORTER 분석
- 합병과 인수 시나리오
- 업계 동향
제4장 세계의 벤라팍신 시장 : 적응증별, 2020-2032년
- 주요 우울 장애
- 불안 장애
- 공황 장애
- 강박 장애
- 외상 후 스트레스 장애
- 기타
제5장 세계의 벤라팍신 시장 : 유형별, 2020-2032년
- 포괄적
- 브랜드화
제6장 세계의 벤라팍신 시장 :제형 및 용량별, 2020-2032년
- 즉시 방출
- 서방형 캡슐
- 서방정
- 경구용액
- 75mg/ml
- 5mg/ml
제7장 세계의 벤라팍신 시장 : 연령층별, 2020-2032년
- 성인(18-64세)
- 고령자(65세 이상)
제8장 세계의 벤라팍신 시장 : 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제9장 세계의 벤라팍신 시장 : 최종 사용자별, 2020-2032년
- 병원
- 정신과 클리닉
- 재택 케어 설정
- 장기 케어 시설
- 재활센터
- 기타
제10장 세계의 벤라팍신 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제11장 경쟁 구도
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan NV
- Hetero Labs Limited
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Amgen Inc.
- Lupin Pharmaceuticals
- Torrent Pharmaceuticals
- Cadila Healthcare
- Glenmark Pharmaceuticals
- Natco Pharma
- Reddy's Laboratories
- Alvogen
- Sandoz(a Novartis division)
제12장 분석가 추천
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제13장 참고문헌과 조사방법
- 참고문헌
- 조사 방법
- 출판사에 대해
Venlafaxine Market is estimated to be valued at USD 3.54 Bn in 2025 and is expected to reach USD 5.26 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.82% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.54 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.82% | 2032 Value Projection: | USD 5.26 Bn |
The global venlafaxine market represents a significant segment within the broader antidepressant pharmaceutical landscape, driven by the increasing prevalence of mental health disorders worldwide. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has established itself as a critical therapeutic option for treating major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.
The drug's dual mechanism of action, which inhibits the reuptake of both serotonin and norepinephrine neurotransmitters, provides enhanced efficacy compared to traditional selective serotonin reuptake inhibitors (SSRIs) in certain patient populations. The market encompasses both immediate-release and extended-release formulations, with the latter gaining preference due to improved patient compliance and reduced side effects. Growing awareness about mental health, destigmatization of psychiatric treatment, and expanding healthcare infrastructure in emerging economies have collectively contributed to the market's steady growth trajectory. Additionally, the availability of generic versions following patent expiration has made venlafaxine more accessible to a broader patient population, further driving market penetration across various geographic regions and healthcare systems globally.
Market Dynamics
The global venlafaxine market is propelled by several key drivers, with the most significant being the rising prevalence of depression and anxiety disorders worldwide, affecting over 300 million people globally according to WHO estimates. The increasing recognition of mental health as a critical component of overall wellness, coupled with reduced stigma surrounding psychiatric treatment, has led to higher diagnosis rates and treatment-seeking behavior. Healthcare providers' growing preference for SNRIs over traditional antidepressants due to their superior efficacy in treating both depression and anxiety simultaneously serves as another major growth driver. The expanding geriatric population, which is more susceptible to depression and anxiety disorders, further amplifies market demand.
However, the market faces notable restraints including the availability of numerous generic alternatives that have significantly reduced profit margins for manufacturers, and the emergence of novel antidepressant classes with potentially better safety profiles. Patent cliff effects have led to intense price competition, while stringent regulatory requirements for new formulations and indications pose additional challenges. Side effects associated with venlafaxine, including withdrawal symptoms, sexual dysfunction, and cardiovascular concerns, may limit its adoption in certain patient populations. Nevertheless, substantial opportunities exist in emerging markets where mental healthcare infrastructure is rapidly developing, and in the development of novel drug delivery systems that could enhance patient compliance and reduce adverse effects. The growing trend toward personalized medicine and pharmacogenomics presents opportunities for targeted venlafaxine therapy based on individual patient genetic profiles, potentially improving treatment outcomes and market growth prospects.
Key Features of the Study
- This report provides an in-depth analysis of the global venlafaxine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global venlafaxine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Hetero Labs Limited, Aurobindo Pharma, Sun Pharmaceutical Industries, Amgen Inc., Lupin Pharmaceuticals, Torrent Pharmaceuticals, Cadila Healthcare, Glenmark Pharmaceuticals, Natco Pharma, Dr. Reddy's Laboratories, Alvogen, and Sandoz (a Novartis division).
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global venlafaxine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global venlafaxine market.
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Major Depressive Disorder
- Anxiety Disorder
- Panic Disorder
- Obsessive-Compulsive Disorder
- Post-Traumatic Stress Disorder
- Other Psychiatric Disorders
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Generic
- Branded
- Dosage Form and Strength Insights (Revenue, USD Bn, 2020 - 2032)
- Immediate-Release Tablets
- 25 mg
- 5 mg
- 50 mg
- 75 mg
- 100 mg
- Extended-Release Capsules
- 5 mg
- 75 mg
- 150 mg
- 225 mg
- Extended-Release Tablets
- Oral Solution
- 75mg/ml
- 5 mg/mL
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adults (18-64 years)
- Geriatric Population (65 years and above)
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Psychiatric Clinics
- Homecare Settings
- Long-Term Care Facilities
- Rehabilitation Centers
- Others
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Hetero Labs Limited
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Amgen Inc.
- Lupin Pharmaceuticals
- Torrent Pharmaceuticals
- Cadila Healthcare
- Glenmark Pharmaceuticals
- Natco Pharma
- Reddy's Laboratories
- Alvogen
- Sandoz (a Novartis division)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Venlafaxine Market, By Indication
- Global Venlafaxine Market, By Type
- Global Venlafaxine Market, By Dosage Form and Strength
- Global Venlafaxine Market, By Age Group
- Global Venlafaxine Market, By Distribution Channel
- Global Venlafaxine Market, By End User
- Global Venlafaxine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Venlafaxine Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Major Depressive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anxiety Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Panic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Obsessive-Compulsive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Post-Traumatic Stress Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Psychiatric Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Venlafaxine Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Venlafaxine Market, By Dosage Form and Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immediate-Release Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 25 mg
- 5 mg
- 50 mg
- 75 mg
- 100 mg
- Extended-Release Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 5 mg
- 75 mg
- 150 mg
- 225 mg
- Extended-Release Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 75mg/ml
- 5 mg/mL
7. Global Venlafaxine Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adults (18-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric Population (65 years and above)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Venlafaxine Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Venlafaxine Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Psychiatric Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-Term Care Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rehabilitation Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Venlafaxine Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form and Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form and Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form and Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form and Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form and Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form and Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hetero Labs Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Torrent Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cadila Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Natco Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alvogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
